Some of the companies agree to cover the trials as long as they already provide the investigator’s liability coverage.
Others tend to reject trials dedicated to novel molecules.
Some companies cannot deal with multicentre trials (not having locations in certain countries).
In any case, they will thoroughly evaluate the quality of the CRO.
Finally, of course, these very specialized companies have a panel of doctors able to identify the risks presented by the study.